Form 4: Prothena Director Lars Ekman Receives Stock Option Grant

Director Lars Ekman was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.

Summary

• Director Lars Ekman received a grant of 27,000 stock options on May 15, 2026.
• The options have an exercise price of $9.76 per share.
• The options are set to expire on May 15, 2036.
• Vesting is scheduled for the earlier of the first anniversary of the grant date or the 2027 annual general meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon continuous service as a director.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual general meeting, assuming continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of annual general meeting dates for vesting is a common governance practice to align director tenure with shareholder cycles.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of May 15, 2027, or the 2027 annual general meeting.

Key Dates

Keywords

Prothena, PRTA, Director Compensation, Stock Options, Insider Transaction, Equity Grant